BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 30554943)

  • 1. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
    Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
    Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
    Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M
    Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When are the BET factors the most sensitive to bromodomain inhibitors?
    Khochbin S
    Transcription; 2013; 4(2):54-7. PubMed ID: 23412362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered regulation and expression of genes by BET family of proteins in COPD patients.
    Malhotra R; Kurian N; Zhou XH; Jiang F; Monkley S; DeMicco A; Clausen IG; Dellgren G; Edenro G; Ahdesmäki MJ; Clausen M; Öberg L; Israelsson E; Belfield G; Vaarala O
    PLoS One; 2017; 12(3):e0173115. PubMed ID: 28248992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain inhibition of MYC-amplified medulloblastoma.
    Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
    Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and characterization of bivalent BET inhibitors.
    Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
    Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.
    Andrieu GP; Denis GV
    Mol Cancer Res; 2018 Apr; 16(4):580-586. PubMed ID: 29437854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
    Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
    Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JQ1: a novel potential therapeutic target.
    Shi X; Liu C; Liu B; Chen J; Wu X; Gong W
    Pharmazie; 2018 Sep; 73(9):491-493. PubMed ID: 30223929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
    Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
    Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.